Biological sex shapes vaccine-induced immunity through interacting genetic, hormonal and cellular pathways, producing systematic differences in both protection and side effects. Research led by Sabra L. Klein Johns Hopkins Bloomberg School of Public Health shows that females often develop stronger antibody and T cell responses to many vaccines, while males may show lower initial responses but sometimes longer-term differences. These patterns are clinically relevant for vaccine effectiveness, dosing strategies and safety monitoring, and they vary by age, pregnancy status and comorbid conditions.
Biological mechanisms
Sex hormones and sex chromosomes are key drivers. Estrogens and progesterone modulate innate and adaptive immune cells, generally enhancing antibody formation and antigen presentation, while testosterone tends to be immunosuppressive. Sabra L. Klein Johns Hopkins Bloomberg School of Public Health has described how X-linked immune genes provide females with a mosaic of expression that can augment responsiveness. Innate sensors and cytokine networks differ by sex, altering early vaccine-triggered inflammation and shaping the magnitude and quality of downstream responses. Akiko Iwasaki Yale School of Medicine has documented how these mechanistic differences influence antiviral immunity and vaccine outcomes in respiratory infections, emphasizing that responses are context-dependent and influenced by vaccine platform and adjuvant.
Consequences for policy and practice
Because females often mount higher antibody titres, they can experience more frequent reactogenicity such as fever or injection-site reactions, which can affect acceptability and uptake in different cultural settings. Conversely, lower responses in males may lead to reduced protection in some groups unless addressed through dosing or booster strategies. Pregnancy adds complexity: maternal immune modulation changes vaccine responses and affects transplacental antibody transfer, with implications for newborn protection in regions with differing healthcare access.
Geography, nutrition and social factors interact with biological sex. In territories with high infectious disease burden or limited cold-chain capacity, sex-differential vaccine performance can amplify health disparities if trials and surveillance do not collect sex-disaggregated data. Cultural norms around healthcare-seeking, gender roles and vaccine hesitancy further shape who is reached and protected.
Collecting and reporting sex-disaggregated immunogenicity and safety data, and designing trials that analyze sex as a biological variable, are essential steps recommended by leading immunologists and public health experts. This approach supports equitable, evidence-based vaccination strategies that account for both biological and sociocultural determinants of immune protection.